Ken Griffin Orgenesis Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$1.18 - $2.24 $18,076 - $34,314
15,319 New
15,319 $29,000

Others Institutions Holding ORGS

# of Institutions
2
Shares Held
134K
Call Options Held
0
Put Options Held
0
View Full List

About Orgenesis Inc.

ORGS Quotes by TradingView
  • Ticker ORGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,545,800
  • Market Cap $28.1M
  • Description
  • Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, ...
More about ORGS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email